In MOC1 tumors, CD44-targeted NIR-PIT might have destroyed smaller number of tumor cells to trigger immune reaction, but combination with CTLA4 blockade might overcome immunosuppression and enhanced anti-tumor responses against MOC1 cells enough to achieve complete remissions along with smaller tumor volume after the combination therapy than CTLA4 blockade alone. The gene discussed is CD44; the disease is neoplasm.